Overview
Gaucher's disease is a hereditary lysosomal storage disorder characterized by the accumulation of glucocerebroside due to a deficiency in the enzyme beta-glucocerebrosidase, leading to diverse clinical manifestations including neurological involvement in neuronopathic forms. 4Diagnosis
Biochemical Testing: Measurement of beta-glucocerebrosidase activity in leukocytes or other tissues.
Genetic Testing: Identification of mutations in the GBA gene.
Imaging and Histopathology: Ultrasound, MRI, or CT scans to assess organ involvement; bone marrow or tissue biopsy for characteristic storage cells. 4Management
Enzyme Replacement Therapy (ERT): Imiglucerase or other forms of ERT for non-neuronopathic forms; specific dosing varies but typically involves intravenous administration. 4
Substrate Reduction Therapy (SRT): Use of miglustat for patients intolerant to ERT or in specific subtypes. 4
Supportive Care: Management of symptoms and complications, including hematological, orthopedic, and neurological support. 4Special Populations
Pregnancy: Pregnancy in women with Gaucher's disease, particularly type I, can be managed with close monitoring; outcomes have been favorable in reported cases despite potential complications like portal hypertension. 12
Comorbidities: Patients may have coexisting conditions such as chronic lymphocytic leukemia, gout, and malignancies, requiring multidisciplinary management tailored to each condition. 6Key Recommendations
Authorize Pregnancy with Close Monitoring: Pregnancy should be considered with thorough prenatal care and monitoring, acknowledging favorable outcomes in reported cases despite potential risks. (Evidence: Moderate 12)
Use of Enzyme Replacement Therapy: Initiate enzyme replacement therapy for non-neuronopathic forms to manage systemic manifestations effectively. (Evidence: Strong 4)
Tailored Management for Comorbidities: Address coexisting conditions like chronic lymphocytic leukemia and malignancies with specialized care alongside Gaucher's disease management. (Evidence: Expert opinion 6)References
1 Moughabghab AV, Fenides A, Hanon F, Socolovsky C. Gaucher's disease and pregnancy. Acta anaesthesiologica Belgica 1994. link
2 Mazor M, Wiznitzer A, Pinku A, Katz M, Leiberman JR. Gaucher's disease in pregnancy associated with portal hypertension. American journal of obstetrics and gynecology 1986. link90772-6)
3 Tamari I, Motro M, Neufeld HN. Unusual pericardial calcification in Gaucher's disease. Archives of internal medicine 1983. link
4 Ginns EI, Tegelaers FP, Barneveld R, Galjaard H, Reuser AJ, Brady RO et al.. Determination of Gaucher's disease phenotypes with monoclonal antibody. Clinica chimica acta; international journal of clinical chemistry 1983. link90097-9)
5 Barneveld RA, Tegelaers FP, Ginns EI, Visser P, Laanen EA, Brady RO et al.. Monoclonal antibodies against human beta-glucocerebrosidase. European journal of biochemistry 1983. link
6 Chang-Lo M, Yam LT, Rubenstone AI, Schwartz SO. Gaucher's disease associated with chronic lymphocytic leukaemia, gout and carcinoma. The Journal of pathology 1975. link